The Food and Drug Administration (FDA) told the maker of Purell to discontinue marketing campaigns that includes claims for avoiding flu and ebola, according to an article on The New York Times website.
The campaigns also claim the product can prevent spread of MRSA and norovirus.
The FDA told Gojo Industries that its claims that Purell could reduce the potential for infection or prevent illnesses violated the Federal Food, Drug and Cosmetic Act.
The agency said it was reclassifying Purell as an unapproved drug, rather than an over-the-counter product.
Sustainability as a Baseline in Healthcare Facilities
Penobscot Valley Hospital Reports Data Security Incident
Ballad Health Acquires Land for Future Unicoi County Hospital
Why Healthcare Facilities Management Is Critical to Patient Safety 
Brookdale Senior Living Announces Acquisition of the Brookdale Galleria Community